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CHO  Chinese hamster ovary
CIA  Collagen-induced arthritis
DMARD  Disease-modifying antirheumatic drug
ELISA  Enzyme-linked immunosorbent assay
EMA  European Medicines Agency
ERA  Enthesitis-related arthritis
eoJIA  Early onset juvenile idiopathic arthritis
Fc  Fragment crystallizable
FDA  Food and Drug Administration
IgG  Immunoglobulin G
INN  International Nonproprietary Name
JIA  Juvenile idiopathic arthritis
MTX  Methotrexate
NIH  National Institute of Health
NSAID  Non-steroidal anti-inflammatory drug
PASI  Psoriasis Area and Severity Index
PD  Pharmacodynamics
PK  Pharmacokinetic
PRESTA  Psoriasis Randomized Etanercept Study in 
Subjects with Psoriatic Arthritis
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Abstract Etanercept was the first tumour necrosis factor 
alpha antagonist approved in the USA for the treatment of 
rheumatoid arthritis, in 1998, and then for other diseases. 
With the etanercept patent set to expire in the EU in 2015, 
a number of etanercept copies have reached the production 
phase and are undergoing clinical trials, with the promise 
of being cheaper alternatives to the reference product. In a 
global scenario that is favourable to the entry of biosimi-
lars, this article discusses the stage of development, manu-
facture, clinical trials and the regulatory process involved 
in the approval of etanercept biosimilars, compiling the 
literature data. Reducing treatment cost is the principal 
attraction for biosimilars to emerge in the global market. 
It is essential for the doctors’ decision on the prescription 
of these medications, as well as for payers, to have clearly 
defined studies of clinical equivalence, quality, and safety 
in order to better evaluate the various copies of etaner-
cept. The authors discuss the need to harmonize differ-
ent national regulations and the introduction of effective 
pharmacosurveillance systems for prompt recognition of 
adverse effects in copies of biopharmaceuticals that differ 
from those found in the reference products.
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PsARC  Psoriatic Arthritis Response Criterion
RA  Rheumatoid arthritis
TNF  Tumour necrosis factor
sTNF  Soluble tumour necrosis factor
tTNF  Transmembrane tumour necrosis factor
rTNF  Tumour necrosis factor receptor
USAN  United States Adopted Names
WHO  World Health Organisation
Introduction
The treatment of rheumatoid arthritis (RA) and other 
forms of spondyloarthritis was revolutionized at the end 
of the 1990s, after the emergence of the so-called tumour 
necrosis factor alpha antagonists (anti-TNFα), which are 
biodrugs, also known as biopharmaceuticals, produced 
using biotechnology [1]. These molecules are fusion pro-
teins and monoclonal antibodies (chimeric and human-
ized) that specifically block the cytokine TNF-α, and in 
some cases, the TNF transmembrane receptor (rTNF), 
reducing the chronic inflammatory process [1]. The first 
biopharmaceutical approved in the USA for the treatment 
of RA, in 1998, was etanercept (a fusion protein) [2, 3]. 
With the near-term expiration of patents covering bio-
logics, pharmaceutical companies around the world are 
developing biosimilars, which in theory are not identical, 
but are similar to the original biologic in terms of their 
protein structure, efficacy, and safety. In the USA, a key 
etanercept patent was due to expire in 2012, but a new 
patent was issued that expires in November 2028 [4, 5]. 
However, in the EU, the patent is set to expire in 2015 
[6].
In this context, this article analyses the current situa-
tion of the principal molecules likely to be biosimilar to 
etanercept, and discusses the production, clinical stud-
ies, and regulation of these molecules, which face the 
difficult challenge of demonstrating similar efficacy and 
safety to the innovative molecule, with lower treatment 
cost.
Etanercept
Etanercept (Enbrel® Amgen-Pfizer) is a fusion protein con-
sisting of a recombinant human TNF receptor (rTNF-p75), 
bound to the Fc portion of an immunoglobulin, which binds 
strongly to soluble TNF-α (sTNF-α) [7, 8]. It has consider-
able molecular weight of approximately 150,000 Da [7, 8]. 
Etanercept is currently used in the treatment of RA, pso-
riatic arthritis (PsA), ankylosing spondylitis (AS), chronic 
plaque psoriasis (Ps), and juvenile idiopathic arthritis (JIA) 
[9–11].
Pre-clinical trials
TNFα, a macrophage-produced cytokine known for its cen-
tral role in the inflammatory response and in autoimmune 
diseases like RA, was discovered in 1975 by the researcher 
Lloyd J. Old. This study enabled anti-TNF-α biopharma-
ceuticals to be developed soon after [12].
With the need to assess the effects of TNF-α and etaner-
cept, it was necessary to carry out in vitro and in vivo 
pre-clinical trials. Although significant differences exist 
between disease models in animals and humans, animal 
in vivo studies allowed for closer study of physiological 
aspects, such as cell signalling, that cannot be mimicked 
in vitro. Type II collagen-induced arthritis (CIA) in mice, 
which presents similarities with RA in humans, was the ini-
tial model used to test the benefits of etanercept in vivo. 
Several groups carried out studies based on this model 
between 1991 and 1993, and all demonstrated a clear 
etanercept benefit for CIA, even when the treatment had 
begun following disease onset [13].
Two pre-clinical trials proved the efficacy of anti-TNF-α 
agents. The first demonstrated that an etanercept infusion in 
the initial stage of CIA in mice was capable of preventing 
destruction of the joint and improving the symptoms [14, 
15]. In the second trial, also in a murine model, in which 
over-expression of the modified human TNF-α gene to pre-
vent degradation of its mRNA is associated with the devel-
opment of RA 4–6 months after the birth of the animals, 
the administration of anti-TNF-α demonstrated the preven-
tion of arthritis [16].
Clinical trials and main indications
Rheumatoid arthritis
Etanercept in association with methotrexate (MTX) is indi-
cated for the treatment of moderate-to-severe active RA in 
adults, when the response to disease-modifying antirheu-
matic drugs (DMARDs), including MTX, was inadequate 
[17, 18].
The effectiveness of etanercept was assessed in a Phase 
II, double-blind, randomized, placebo-controlled clinical 
trial [19]. In this trial, 234 patients with active RA with 
treatment failure to at least one and not more than four 
DMARDs were evaluated. Doses of 10 or 25 mg of etaner-
cept or placebo were administered subcutaneously, twice a 
week, for 6 consecutive months. At 3 months, 62 % of the 
patients treated with 25 mg of etanercept and 23 % of the 
patients who received placebo achieved a 20 % response as 
per American College of Rheumatology criteria (ACR20). 
At 6 months, 59 % of the group receiving 25 mg etaner-
cept and only 11 % of the placebo group achieved 
ACR20. Respectively, 40 and 5 % achieved ACR50 and 
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approximately 15 % and just over 5 % achieved ACR70 
at 6 months. In this study, patients treated with etaner-
cept achieved better outcomes in terms of disease activity 
and quality of life. It was also found that the therapeutic 
response is dose-dependent, as the results with 10-mg 
etanercept were intermediate to those obtained with pla-
cebo and etanercept [19].
Psoriatic arthritis and psoriasis
The efficacy of etanercept in the treatment of PsA was 
demonstrated in a placebo-controlled randomized clini-
cal trial, in which 60 patients with active PsA that was 
not responsive to non-steroidal anti-inflammatory drugs 
(NSAIDs) received etanercept at a dose of 25 mg subcuta-
neously twice a week, or placebo [20]. In each group, 47 % 
of patients continued to use MTX at a dose of up to 25 mg/
week. At week 12, 87 % of patients treated with etaner-
cept achieved the Psoriatic Arthritis Response Criterion 
(PsARC) compared with 23 % of the placebo group. Fur-
thermore, in 77 % of patients using etanercept, the response 
was obtained in 4 weeks or less. Similar responses were 
observed using ACR20, ACR50, and ACR70 criteria. 
Etanercept was also effective in improving skin lesions, as 
assessed by Psoriasis Area and Severity Index (PASI) and 
through the clinical improvement of active lesions identi-
fied individually [20].
The optimal dosage was evaluated by the Psoriasis 
Randomized Etanercept STudy in Subjects with Psori-
atic Arthritis (PRESTA) clinical trial, which compared the 
efficacy of two therapeutic regimens of etanercept (50 mg 
twice weekly or 50 mg once weekly) in patients with Ps 
and PsA. This study revealed that higher doses of etaner-
cept are related to better clinical outcomes in relation to 
skin lesions in week 12. However, both regimens obtained 
significant improvement in skin lesions and other aspects, 
such as arthritis, enthesitis, and dactylitis, at week 24 [21].
Concomitant use of MXT for the treatment of Ps and 
PsA is allowed, but in studies involving the five anti-TNF-α 
available on the market (adalimumab, etanercept, and inf-
liximab, golimumab and certolizumab pegol), there appears 
to be no difference in clinical or imaging response with 
respect to PsA [22, 23].
Ankylosing spondylitis
Etanercept is indicated for the treatment of adults with 
severe active AS that is unresponsive to conventional ther-
apy [17, 24–26].
The efficacy of etanercept in AS was observed through 
a double-blind, placebo-controlled randomized trial involv-
ing 277 patients with active disease, who received 25 mg 
of etanercept or placebo twice weekly for 24 weeks [25]. 
Outcome measures were Assessments in Ankylosing 
Spondylitis 20 % response (ASAS20) and the percent-
age of patients achieving higher ASAS. The measures 
were assessed at 2, 4, 8, 12, and 24 weeks. The outcomes 
showed high efficacy of etanercept at 12 weeks, and the 
ASAS20 was achieved by 82 (59 %) of the 138 patients 
in the etanercept group and by 39 (28 %) of the 139 
patients in the placebo group. At 24 weeks, the ASAS20 
was achieved by 79 (57 %) in the etanercept group and by 
31 (22 %) patients in the placebo group. The difference 
between groups was significant as early as 2 weeks and was 
maintained over the 24-week study duration. According 
to Davis and collaborate, the etanercept group had signifi-
cantly greater improvements in all individual components 
of the ASAS response criteria at weeks 12 and 24. Adverse 
events occurred in similar proportions of patients in each 
treatment group during the study.
Juvenile idiopathic arthritis
The most common childhood chronic rheumatic disease is 
JIA [27–29]. For the treatment of this disease, etanercept 
was used for patients aged 4–17 years who did not respond 
to one or more DMARDs [30].
Lovell et al. [31] conducted the first randomized, con-
trolled study, demonstrating the safety and efficacy of 
etanercept in the treatment of polyarticular JIA. After that, 
non-controlled prospective trials were carried out, which 
corroborated the efficacy of etanercept in the treatment of 
polyarticular JIA, shown by Lovell [32–36].
The safety and efficacy of etanercept in specific cat-
egories of JIA, such as extended oligoarticular JIA 
(eoJIA), enthesitis-related arthritis (ERA), and PsA have 
not yet been completely elucidated [37–39]. Therefore, 
the Phase IIIb open-label, multicenter CLinical Study In 
Paediatric Patients of Etanercept for Treatment of ERA, 
PsA, and Extended Oligoarthritis (CLIPPER) trial was 
designed, which is currently in progress. The first part of 
the follow-up, conducted over 1 year, showed that treat-
ment with etanercept 0.8 mg/kg once weekly is safe and 
effective for paediatric patients with eoJIA, ERA, and 
PsA [40].
Pharmacodynamics (PD)
The rTNF-p75 of etanercept specifically blocks sTNF and 
lymphotoxin α (TNFβ), promoting lowering of serum lev-
els of this cytokine and resulting in reduction of the inflam-
matory process [41, 42]. There are also reports of binding 
with transmembrane TNF (tTNF) [43]. The fragment, crys-
tallizable (Fc)-fusion region in rTNF, normally used to acti-
vate the complement system in immunoglobulin G (IgG), 
did not demonstrate this action in etanercept [44].
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Research has also demonstrated that etanercept can 
make cells more susceptible to apoptosis through a still 
unknown mechanism, in experimental colitis [45], RA [46], 
and in vitro studies with macrophages [47]; however, these 
effects did not demonstrate a clinical impact on RA or any 
other disease [48].
Pharmacokinetics (PK)
Neonatal Fc receptors (FcRn) play an important role in 
the rescue of IgG, through their presence in the endocytic 
pathway in endothelial cells [49]. When IgG is internalized 
by means of pinocytosis, Fc receptors bind to IgG and pre-
vent its degradation in the endosomal acid, recycling it to 
the cell surface, releasing it at the basic pH of blood, and 
thereby preventing it from undergoing lysosomal degrada-
tion [50]. This mechanism may explain the longer half-life 
of IgG in the blood, compared with other Isotopes. It has 
been demonstrated that combining certain drugs with the 
Fc domain of IgG significantly increases its half-life [50]. 
It is for this reason that etanercept is a fusion protein of 
TNF and Fc.
Etanercept absorption is initiated at the site of subcuta-
neous injection, with time to peak concentration of around 
48–60 h, and elimination from the body occurs slowly with 
a terminal half-life between 70 and 100 h [51].
The pharmacokinetic parameters of etanercept predict 
that a dose of 0.8 mg/kg once weekly will generate sys-
temic exposure comparable to 0.4 mg/kg twice weekly. 
Dose adjustment of etanercept is considered only when 
administered in conjunction with warfarin, digoxin, or 
MTX [51].
Immunogenicity
The immunogenicity caused by the production of anti-drug 
antibodies (ADA) is also an important factor, and in many 
cases, an effect that prompts discontinuation of treatment 
[52, 53]. After long periods of treatment, ADA have been 
detected by the immunoenzymatic essay (ELISA). ADA 
may cause neutralization of the molecule, affecting PD 
and PK, making the treatment ineffective [54]. However, 
etanercept was presented as the molecule with the lowest 
ADA among all other anti-TNFs, but the answers about it’s 
low-immunogenicity still unclear [52, 54, 55].
The causes of immunogenicity can be chimeric bio-
logical drugs (e.g. infliximab), even humanized molecules 
(e.g. adalimumab) and fully humanized biological drugs 
(golimumab)—most the cases the residual immunogenic-
ity resides in the CDR regions [56]—glycosylation profiles, 
fermentation, purification, formulation (aggregate forma-
tion), administration mode (i.m., i.v. and s.c.), dosing, deg-
radation products and contaminants [57].
Pharmacosurveillance and safety
Since the approval of etanercept (Enbrel® Amgen-Pfizer) 
in 1998 by medicine regulatory agencies such as the EMA 
(European Medicines Agency) and FDA (US Food and 
Drug Administration), constant updates on its benefits, 
risks, efficacy, and safety have been necessary, a role exer-
cised by pharmacosurveillance [58, 59]. In nearly more 
than 20 years of marketing, adverse effects were found 
such as persistent diseases (tuberculosis, hepatitis, and 
other infections) and cancer [52, 60–63].
The pharmacosurveillance plan includes retrospective 
and prospective controlled clinical trials with long-term 
follow-up and adverse-event reports. This information, 
after being collected and revised, is made available to doc-
tors and patients by means of scientific articles and letters 
to the health agents, in addition to updating of the package 
product information leaflet with new side effects, formula-
tion, and dose, based on the studies [64]. Another objec-
tive of the pharmacosurveillance program of the FDA is 
education and communication to the community. The first 
was created by the Immunex Corporation to facilitate self-
reporting of adverse events, and the other is the healthcare 
program ENLIVEN, which is responsible for providing 
educational information and support services, as well as 
updates on the medicine to etanercept users, eight times a 
year [58].
The pharmacosurveillance study conducted by the 
FDA and EMA provided recognition of severities such as 
infections and sepsis—particularly in immunosuppressed 
patients who used etanercept, and the reactivation and 
worsening of symptoms of tuberculosis and hepatitis B 
[58]. The risk of reactivation of latent tuberculosis is inher-
ent to the use of all anti-TNF agents, but etanercept appears 
to present lower risks, compared with other biopharmaceu-
ticals [65]. Other side effects of note include lymphopro-
liferative disorders, skin cancer, haematological reactions 
such as thrombocytopenia, pancytopenia, and neurological 
disorders ranging from headache to more severe demyeli-
nating diseases, and congestive heart failure, for example, 
have all been seen in patients with AS [65].
All this knowledge and updating allow new formulations 
and new behaviours in relation to etanercept, such as detec-
tion of tuberculosis prior to its use, and monitoring and 
suppression of the medication in the event of infection and 
immunosuppression [66].
Manufacture of biosimilars
The production of biosimilars follows a similar process 
as the original biopharmaceuticals. The processing of 
molecules such as insulin, somatropin, interferons, and 
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antagonists, including etanercept, starts with the use of 
mammalian cell lineages for replication of recombinant 
DNA to obtain the desired protein [67]. There are various 
means of synthesis available for therapeutic proteins, such 
as plant cells, yeasts, and bacteria (in particular Escherichia 
coli). However, the choice of mammalian cells, particularly 
Chinese hamster ovaries (CHOs) or murine lymphoid cells, 
for the production of etanercept and biosimilars, is neces-
sary for post-translational changes and glycosylation pat-
terns of Fc and rTNF portions, which are similar to those of 
human cells [68].
After stabilization of the master cell lineage, produc-
tion of the molecule of interest begins. The molecule 
goes through a series of fermentation processes, scaling 
(upstream process) purification (downstream process), the 
pharmaceutical formulation, and finally bottling of the 
biopharmaceutical [69]. Besides innate growth deviations, 
any change in these manufacturing steps will lead to vari-
ability of the biosimilar molecule, and may affect its effi-
cacy and safety, hence the need for clinical studies [70, 71].
The pharmaceutical formulation strategy is a critical 
step and needs to be accurate. The knowledge about physi-
cal and biological properties of the biological drug orien-
tate the formulation process. Important components of 
protein formulations are pH, stabilizer, solubilizer, buffer, 
and tonicity modifier (bulking agent). The typical stabil-
ity problems observed in protein pharmaceuticals are non-
covalent aggregation, covalent aggregation, deamidation, 
cyclic imide, and cleavages [72]. This process can affect 
directly the efficacy (e.g. immunogenicity) and safety (e.g. 
adverse events) of a biological drug.
As a result, following the recommendations of the EMA 
and FDA, studies have used modern techniques of mass 
spectrometry for the analysis of etanercept ‘intended copy’ 
produced in China [71, 73]. Identification of the primary 
amino acid sequence of biosimilars, comparison of both 
parts of the protein separately and their glycosylation pat-
terns, among other characteristics, have shown differences 
between the biosimilars manufactured. However, even bio-
similars that differed from etanercept presented equivalent 
bioactivity [71]. This highlights an issue that has yet to be 
resolved by the emerging biopharmaceutical industry. The 
non-existence of a protocol of standardized procedures for 
the manufacture of biosimilars, and the lack of a sharing 
of know-how on new successful processes between compa-
nies [69], have hindered the establishment of a number of 
analytical methods for comparison between biosimilars and 
their reference products, or between batches already manu-
factured that could be considered sufficiently safe [73, 74]. 
Thus, the only way to ensure the safety and efficacy of the 
biosimilars manufactured is through conducting pre-clini-
cal studies and clinical trials, and implementing effective 
pharmacosurveillance plans [74].
Regulation
The regulation for biosimilar medicines has evolved over 
the past 10 years. In 2005, the EMA Committee for Medici-
nal Products for Human Use (CHMP), which is responsible 
for the scientific evaluation of human medicines authorized 
and marketed in Europe, published their first regulatory 
guideline, highlighting the required data for the licensing 
application for a biosimilar agent [5]. In May 2012, the 
guideline was published for approval of biosimilars con-
taining monoclonal antibodies, which came into effect on 1 
December 2012 [75].
Prior to 2010, the FDA had limited authority to approve 
biosimilars, resulting in delays in the development of these 
agents in the US, compared with Europe. With the prom-
ulgation of the Patient Protection and Affordable Care Act 
(the health reform), all this has changed. In March 2010, 
the law known as the Biologics Price Competition and 
Innovation Act (BPCIA) created a shortened approval route 
for biopharmaceuticals that show high similarity or inter-
changeability with the already-licensed biological product 
[76]. The law grants a 12-year exclusivity period for the 
manufacturer of an innovative biopharmaceutical, during 
which a given biosimilar product cannot be approved [77]. 
To stimulate the development of biosimilars, the BPCIA 
guarantees 1 year of exclusivity of marketing rights to the 
first biosimilar that is approved as being interchangeable 
with the reference product. In February 2012, the FDA 
published three preliminary documents on the development 
of biosimilar products to assist industry in the development 
of these in the USA [78–80].
The World Health Organization (WHO) guidelines on 
the approval of biosimilars share the same principles as the 
FDA and EMA guidelines in relation to the requirement of 
comparative data on chemistry/manufacture, pre-clinical 
studies, and Phase I–III clinical trials [81]. However, the 
regulatory environment around the world is extremely vari-
able. In Latin America, countries tend to follow the WHO 
guidelines, but despite advances in the legislation, there is 
no harmonization of the regulations and many copy prod-
ucts have been approved without adequate evaluation, 
lacking in particular, in good-quality clinical trials. Unfor-
tunately so far, two copies of etanercept already marketed 
in Mexico and Columbia cannot be considered biosimilars 
[81]. The full exercise of biocomparability requires the 
evaluation of various issues, in order for a molecule to be 
considered biosimilar. Issues such as analytical procedures 
and aspects of manufacturing of biological products are 
crucial for the analysis of biocomparability. These char-
acteristics will therefore be precursors to finding the most 
appropriate and most sensitive study model for the evalu-
ation of clinical outcomes that can assess the comparabil-
ity of the biosimilar to the reference molecule. According 
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to the EMA guideline, the dosage and route of administra-
tion of the biosimilar should obey the same criteria as those 
used by the reference molecule [77].
Another problem that will certainly affect the marketing 
of biosimilars is interchangeability, defined as the ability of 
two products to be exchanged with each other without risk 
of significant adverse effects on the patient’s health [82, 
83]. Such interchangeability or interpermutability that is 
already a standard procedure for small molecules (gener-
ics) has prompted intense debate for the application in the 
case of copies of biopharmaceuticals. Whether a biosimi-
lar needs to be interchangeable with a reference product, 
and the requirements for this procedure are issues that are 
still under much clinical and regulatory debate. The accept-
ance of interchangeability may vary from country to coun-
try, and there are several wider implications for patients, 
prescribers, and health systems. We believe that regulatory 
bodies should have transparent processes that give peace of 
mind to all those involved and maintain scientific standards 
of the choice for interchangeability of the highest level and 
rigour. In Europe, for example, replacing a reference prod-
uct with a biosimilar is the national responsibility of each 
country [84]. In practice, replacement with a biopharma-
ceutical is not permitted in any European country [85], and 
it is not recommended by WHO or medical societies [86, 
87]. A further issue for which there is no global standardi-
zation is the extrapolation of indications between diseases 
of different etiologies (neoplastic disease versus inflam-
matory disease). Among anti-TNFs, for example, although 
the therapeutic target of the different molecules are the 
same, TNF-α, different modes of action are demonstrable 
in diseases in which anti-TNFs are effective: PsA, RA, and 
Crohn’s disease.
Biosimilars of etanercept
Clinical considerations for the definition  
and use of biosimilars
It is well known that the demand of companies interested in 
producing biosimilars of etanercept has attracted the world’s 
attention (Fig. 1). Synthetic molecules have a simple and 
replicable molecular structure, enabling the production of 
so-called generics, which are identical copies of the original 
molecules [82]. Unlike chemical medicines, biopharmaceu-
ticals have a highly complex protein structure and manu-
facturing process, making it impossible to produce identical 
copies. The commonly used term biosimilar is a regulatory 
definition that ultimately defines a molecule that is similar in 
terms of structure, efficacy, and safety in relation to the refer-
ence biopharmaceutical. Therefore, biosimilars require spe-
cific adjustment for their production and marketing [83, 88].
In order to be approved, biosimilars must go through a 
series of studies that include quality testing, pre-clinical and 
clinical trials demonstrating tolerance, pharmacokinetics, and 
pharmacodynamics similar to the reference biopharmaceuti-
cal product [88]. The biosimilars studied also require Phase 
III clinical trials, which may be of equivalence or non-infe-
riority in relation to the original molecule. If the comparison 
fails at any stage, the product cannot be elected as a biosimi-
lar, and the term intended copy is often applied to products 
with incomplete biocomparability exercises [83, 89].
Biosimilars in the clinical trial phase
There are few results published in databases from clinical 
trials on biosimilars of etanercept currently in development. 
Fig. 1  Profile of companies that are developing biosimilars or ‘intended copies’ around the world
203Rheumatol Int (2015) 35:197–209 
1 3
In relation to studies found in the databases, we found the 
HD203, an etanercept biosimilar candidate developed by 
the South Korean company Hanwha Chemical, which is in 
a Phase I clinical trial. Yi et al. [90] carried out a double-
blind, randomized, single-dose, two-sequence, and crosso-
ver study in 37 volunteers, which satisfied the bioequiva-
lence criteria. However, the immunogenicity of HD203 was 
not evaluated in these studies and will therefore require fur-
ther studies (e.g. studies with multiple doses).
Gu et al. [91] conducted a Phase I, single-dose, open-
label, crossover trial in two sequences, involving 21 healthy 
male Korean volunteers. The study compared the pharma-
cokinetic properties of etanercept and its potential biosimilar 
TuNEX®, produced by the Taiwanese company TSH Biop-
harm Corp. This clinical trial showed that the biosimilar was 
well tolerated and met the bioequivalence criteria established 
by the South Korean authorities. All adverse effects reported 
were moderate, the most common ones being headache, 
inflammation of the throat, and epistaxis. However, this 
study had some limitations as it was a single-dose, open-
label trial involving a small number of volunteers. New stud-
ies are therefore needed to access the tolerability, pharmaco-
dynamics, and efficacy of TuNEX® in patients.
In Brazil, the largest market in Latin America, Bionovis 
(a joint venture between EMS, Aché, Hypermarcas, and 
União Química) has received approval from the Brazilian 
National Health Surveillance Agency (ANVISA) to conduct 
a clinical trial with 318 patients, to evaluate the efficacy of 
an etanercept biosimilar molecule [92]. According to the 
information portal of the Ministry of Health of the Brazil-
ian government, Bionovis formed a partnership with Merck 
Serono and, in addition to the etanercept biosimilar, it will 
produce a further six biosimilar molecules. However, there 
is no further information regarding pre-clinical and clinical 
trials or the manufacturing process of the molecule [92, 93].
Information on other biosimilars under development is 
registered with NIH (US National Institutes of Health) at 
Clinicaltrials.gov. To date, no results from these studies 
have been published in databases (Table 1).
Possible biosimilars candidate in the pre-clinical trial phase
Various biopharmaceuticals with similarity to etanercept 
are in the pre-clinical phase, particularly with a view to 
molecular characterization and evaluation, using in vitro 
and in vivo models. PRX-106 is another possible biosimi-
lar that is being developed by the Israeli company Protalix 
Biotherapeutics and is in the pre-clinical phase. This mol-
ecule is produced from plant cell cultures [77, 94].
In Brazil, Libbs, in partnership with the Argentinian 
group Chemo, has also announced the production of a 
candidate etanercept biosimilar [95]. The partnership also 
includes mAbxience, a Swiss-based biotechnology com-
pany that belongs to Chemo Group that specializes in the 
development and manufacture of biosimilars [95]. Accord-
ing to the mAbxience website, the molecule is currently in 
the process of production scale-up, and pre-clinical trials 
will be conducted soon [96].
The Indian company Avesthagen has conducted pre-
clinical trials on AVG01 (AVENT™). The molecule dem-
onstrated high structural and pre-clinical similarity with 
etanercept [97]; however, there is a need for clinical trials 
Table 1  Profile of clinical trials on etanercept biosimilars according to international regulations
Pk pharmacokinetic, MTX methotrexate, RA (−+) moderate and severe rheumatoid arthritis, S safety, E efficacy, I immunogenicity
Sponsor Biosimilar Condition Phase Estimated 
recruitment
Experimental design Dose 
(mg)
Parameter References
Samsung Bioepis SB4 RA (−+) III 498 SB4 versus etanercept 50 S, E NIH [113]
Samsung Bioepis SB4 Healthy I 138 SB4 versus etanercept (EU)  
and etanercept (US)
50 PK, S, I NIH [114]





RA, MX III 129 TuNEX® versus MTX  
and Placebo
15–25 S, E, I Gu et al. [91], Chen 
et al. [116]
LG Life Sciences LBEC0101 Healthy I 36 LBEC0101 versus etanercept 25 PK NIH [117]
Daewoong  
Pharmaceutical
DWP422 RA I 38 DWP422 versus etanercept 25 PK, S NIH [118]





CHS-0214 Healthy I – CHS-0214 versus etanercept – PK Yi et al. [119]
Bionovis (Merck 
Serono)
– – – 318 unknown versus etanercept – E Scaramuzzo [92], 
Brazilian Ministry 
of Health [93]
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to compare efficacy and safety in humans. The manufacture 
of biosimilar molecules is expanding rapidly in India, but 
without rigorous clinical trials, these molecules will be lim-
ited to their local market or to countries with limited reg-
ulation on the use of biopharmaceutical copies for which 
there are no comparative clinical trials [97].
The Korean company D-Pharm Ltd. has conducted pre-
clinical trials on a possible etanercept biosimilar. In these 
studies, the molecule, denominated TNFR-hyFc, showed 
high similarity with etanercept in terms of its glycoprotein 
profile and pharmacokinetics [98, 99].
Intended copies of etanercept
The term ‘intended copy’ or ‘non-comparable biologic’ 
differs from the definition of a biosimilar in that it lacks a 
complete biocomparability study and/or clinical trials, or 
else only limited clinical trials were conducted on it, and 
thus become copies that do not present similar safety and 
efficacy to the innovative product [100, 101]. However, 
some biologicals have been marketed without clinical trials 
in countries with less strict regulation [82]. Many intended 
copies cannot be recognized as biosimilars, as they do not 
have any studies registered with ClinicalTrials.gov. How-
ever, in some cases, the trials, although registered, were not 
actually carried out, and in others, there is no scientifically 
reliable available data in indexed journals. For the develop-
ment of this article, it was sometimes necessary to use data 
from websites of companies that in many cases we consid-
ered inaccurate or non-transparent. This led to a limited 
analysis for classification of the described products.
Yisaipu, from Shanghai CP Goujian Pharmaceutical Co., 
is a fusion protein that has already been marketed in the Chi-
nese market. However, data are needed on its non-inferiority 
in relation to etanercept to determine its biosimilarity [77, 
102]. In Colombia, Yisaipu is marketed under the brand name 
Etanar® and is not considered a biosimilar, but an intended 
copy, as it has only one limited clinical trial, which was not 
an equivalence study with the product in question [103].
In India, the company Cipla is marketing an intended 
copy, which according to the terms of the partnership, will 
be produced by the Chinese company Shanghai CP Gou-
jian Pharmaceutical Co., the same company that produces 
Yisaipu. This molecule also lacks data based on the inter-
national legislation for it to be accredited as a biosimilar 
molecule [104].
Another country that is marketing an intended copy is 
Mexico, with Probiomed selling a biopharmaceutical under 
the brand name of Infinitam®. There has only been one study 
(unpublished), which assessed the efficacy and safety of this 
biopharmaceutical associated with MTX versus etanercept 
associated with MTX in patients with moderate and severe 
RA, however, is not a head-to-head comparison [105].
Expert opinion
The globalized introduction of biopharmaceuticals has 
revolutionized the treatment of various diseases for which 
there was no treatment or the traditional treatments were 
ineffective or unsafe. Anti-TNF agents, for example, pro-
vide great benefit to patients with RA, spondyloarthritis, 
Ps, and intestinal inflammatory diseases. However, treat-
ment with this class of products when compared with tradi-
tional molecules is more costly from a pharmacoeconomic 
point of view. Therefore, access to these medicines is still 
limited, as they cause a great impact on health budgets of 
various countries. With the failure of patent applications of 
some innovative biopharmaceuticals, a pathway has been 
cleared for the production of their copies. Thus, the poten-
tial cost reduction of treatment with biopharmaceuticals is, 
in our view, the biggest attraction for the emergence of so-
called biosimilar molecules on the global market.
Due to intrinsic complexity in copying biopharmaceuti-
cals, based on the understanding that two lines of cell pro-
duction are different (reference product and copy) and usu-
ally developed independently, copies cannot be considered 
identical. This is recognized by various regulatory agen-
cies, and the European regulatory authorities have, over 
the past 10 years, carefully established the term biosimilar, 
recognizing the fact that although similar to the reference 
products, they are not absolutely identical [106, 107]. The 
extensive manufacturing and clinical data available to the 
innovator molecule is proprietary, and includes specific 
details for cell line development and genetic construct, raw 
materials, cell culture conditions, purification parameters 
as well as formulation and drug delivery. These details are 
therefore not available to the manufacturers of any potential 
biosimilar product, which presents as a “knowledge gap” 
[108]. Due to the complexity of biological systems, and 
the nature of biotechnological manufacturing, any attempt 
to copy an originator molecule cannot result in an identical 
product. For this reason, providing sufficient comparability 
and clinical data can be provided, after regulatory approval, 
such follow-on biologics are termed “biosimilar”. Follow-
on biologics which have not obtained regulatory approval 
are not regarded as biosimilars.
Etanercept is an attractive molecule when it comes to the 
production of copies, due to its proven efficacy, consoli-
dated market, and high cost [82]. Even so and despite the 
loss of the etanercept patent outside the USA, our date sur-
vey revealed very few companies capable of manufactur-
ing and marketing etanercept copies. Many of them, having 
already obtained a copy through processes of genetic reen-
gineering, are committed to conducting the entire compara-
bility exercise with the reference product.
It is also of critical importance to demonstrate biochemi-
cal comparability for large, complex biomolecules, such as 
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etanercept, that the necessary detailed structural biochemi-
cal and in vitro characterization studies are completed which 
may potentially impact the potency, clearance, and safety, 
or immunogenicity profile of such biologics are executed. A 
pre-requisite for each process modifications for the manufac-
ture of biologicals is that extensive biochemical characteri-
zation analyses are performed to demonstrate comparability 
with the product from the previously licensed process.
Such comparability evaluations need to be executed 
in accordance with ICH Guidelines for the assessment of 
Comparability of Biotechnological/Biological Products 
[109] and are subsequently subject to the appropriate regu-
latory review and approval processes. Supplemental to these 
data are also the comprehensive detailed, extensive set of 
patient safety data from pharmacovigilance programs exe-
cuted throughout the development and commercial history.
Unfortunately, a few companies, particularly in Asia 
and Latin America, are marketing their products without 
any head-to-head comparison trials with etanercept [77, 
81, 102–105]. Consequently, finding data on the safety and 
efficacy of these copies is very difficult. Thus, a compre-
hensive understanding of these products represents a great 
challenge for clinical practice and for researchers.
The current scenario of the production of etanercept 
copies is very heterogeneous. There are molecules whose 
pre-clinical development phase has been completed suc-
cessfully, and molecules whose Phase I or Phase III clinical 
trials are in progress. It is therefore expected that marketing 
approval for some of these products will be obtained in the 
coming years by the regulatory agencies, which have rigor-
ous and specific legislation for biosimilars. It is vital that 
any biosimilar (to etanercept or other biologic) will meet 
the same levels of biochemical, in vitro characterization, 
and in vivo safety and efficacy as have been demonstrated 
for the innovator biologic. Such product comparability and 
clinical data are paramount to ensuring patient safety. What 
is also most notable from a number of recent publications 
are the specific omissions in the scope of the analyses per-
formed for key product quality attributes, which highlights 
the previously described “knowledge gap” [110].
Production of biosimilars is further complicated through 
the ‘knowledge gap’, as subtle changes to production condi-
tions such as temperature or pH can have a profound effect on 
the properties of a large protein molecule, such as the extent 
of protein folding, glycosylation pattern or degree of aggrega-
tion. Product quality parameters such as protein glycosylation 
can in turn influence the therapeutic effect and safety profile 
of the biologic and need to be thoroughly assessed on a case–
case basis [111]. For these reasons, the need for clinical tri-
als in order to demonstrate the safety and efficacy profiles of 
biosimilars for each indication has been identified [108, 112]. 
This position precludes interchangeability by a pharmacist 
between a biosimilar and the originator’s product.
Another notable scenario in countries like Brazil, 
attracted our attention, wherein certain manufacturers of 
biosimilars have formed partnerships with local national 
companies for the development of their products. In this 
partnership, production technology is transferred with the 
guarantee that in the future, the government will prioritize 
the purchase of these products over those of other manufac-
turers, for a period of up to 5 years [93].
It is essential for doctors’ decision-making on the pre-
scription of etanercept biosimilars, as well as for payers, 
to have well-characterized studies of equivalence or non-
inferiority, in order to ensure accurate assessment of their 
copies. The aims of these comparative clinical trials are to 
collect initial data for follow-up and to assess uncertainties 
related to the safety and efficacy of a biosimilar compared 
with the innovative product. Certainly, regulations have 
advanced in the sense of guaranteeing scientific rigour in 
the process of approval of copies, and for this reason, the 
term biosimilar has been widely used for products that are 
proven to have physical and chemical similarity and also 
similarity based on pre-clinical and clinical trials. Despite 
this, we found some inconsistencies in which, despite the 
advanced and rigorous legislation on the approval of bio-
similars, as in the case of Mexico, two products that were 
copies of etanercept had received approval without the veri-
fication of equivalence trials to determine comparability 
with the reference product [81, 105].
At the national and global level, it is essential to ensure 
harmonization of the different regulations for the approval 
of biosimilars, particularly in relation to the introduction of 
effective pharmacosurveillance systems for easier recognition 
of adverse effects of copies of biological medicines that are 
different from those already found in the reference products. 
Pharmacosurveillance requires sufficient identification of 
a suspect agent of an adverse event; thus, it is essential for 
health professionals to be accurate in the identification of a 
product during the process of communicating (reporting) 
an adverse event. Biosimilars are a challenge in this regard, 
because the identification of the active substance [through an 
International Nonproprietary Name (INN)] does not provide 
a sufficient description to differentiate possible safety prob-
lems between the biosimilar and the reference product, in the 
process of manufacture and handling. For this, we believe that 
biosimilars must be quickly identified as distinct medicines, 
with different INN/USAN. The brand name, for example, 
should also be used to ensure specificity, within an accurate 
regulatory system. When there is no clarity in this distinction, 
there is a high likelihood that this will hinder the identifica-
tion of an agent suspected of causing a serious adverse event.
In case the originally authorized medicinal product has 
more than one indication, and this is the case for antiTNF 
agents, the efficacy and safety of the medicinal product 
claimed to be similar has to be justified or, if necessary, 
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demonstrated separately for each of the claimed indica-
tions. In certain cases, it may be possible for regulatory 
authorities to extrapolate therapeutic similarity shown in 
one indication to other indications of the reference medici-
nal product. The Justification will depend on clinical expe-
rience, available literature data, whether or not the same 
mechanisms of action or the same receptor(s) are involved 
in all indications. Some concerns have been raised with the 
extrapolation of antiTNFs because of the different mode of 
actions in different diseases like RA and psoriasis (although 
the therapeutic targets are the same).
Finally, it makes good sense that the pharmacosurveil-
lance requirements for biosimilars be as rigorous as those 
required for the reference products.
To monitor adverse effects and promote long-term safety 
for patients, as has already occurred with etanercept, all 
of its potential biosimilars should have post-marketing 
requirements, risk managements plans, and other phar-
macosurveillance protocols, aligned with those required 
by etanercept. When it comes to biosimilars, everything 
is changing quickly: regulations, new manufacturers, and 
health policies, making this a very dynamic environment. 
This article, based on scientific information and the indexed 
literature, is an attempt to collate the various experiments 
currently in progress with etanercept copies. We also take 
this opportunity, as clinicians, to emphasize the aspects 
related to the pharmacosurveillance of biological products. 
We recognize that the global scenario will probably change 
considerably with the presence of new players in the com-
ing years, which will certainly require a new revision of 
this article.
Acknowledgments Editorial/medical writing support was provided 
by Samantha Forster of Engage Scientific Solutions and was funded 
by Pfizer Inc.
Conflict of interest Azevedo, Galli, Kleinfelder, D’Ippolito and 
Urbano declare no conflict of interests relevant to this work. The 
review was not commissioned and was externally peer reviewed.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necro-
sis factor antagonist mechanisms of action: a comprehensive 
review. Pharmacol Ther 117:244–279. doi:10.1016/j.pharmth
era.2007.10.001
 2. Pisetsky D (1998) New treatments for rheumatoid arthritis. 
Health News 4:3
 3. Feldmann M, Charles P, Taylor P, Maini RN (1998) Biologi-
cal insights from clinical trials with anti-TNF therapy. Springer 
Semin Immunopathol 20:211–228. doi:10.1007/BF00832008
 4. Harrison C (2012) Enbrel patent surfaces. Nat Biotechnol 
30:123. doi:10.1038/nbt0212-123
 5. Scheinberg MA, Kay J (2012) The advent of biosimilar thera-
pies in rheumatology—“O brave new world”. Nat Rev Rheuma-
tol 8:430–436. doi:10.1038/nrrheum.2012.84
 6. Mullard A (2012) Can next-generation antibodies offset bio-
similar competition? Nat Rev Drug Discov 11:426–428. 
doi:10.1038/nrd3749
 7. Murray KM, Dahl SL (1997) Recombinant human tumor necro-
sis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheu-
matoid arthritis. Ann Pharmacother 31:1335–1338
 8. Jarvis B, Faulds D (1999) Etanercept: a review of its use in 
rheumatoid arthritis. Drugs 57:945–966
 9. Spencer-Green G (2000) Etanercept (Enbrel): update on thera-
peutic use. Ann Rheum Dis 59:i46–i49. doi:10.1136/ard.59.su
ppl_1.i46
 10. Culy CR, Keating GM (2003) Spotlight on etaner-
cept in rheumatoid arthritis, psoriatic arthritis and juve-
nile rheumatoid arthritis. BioDrugs 17:139–145. 
doi:10.2165/00063030-200317020-00006
 11. Braun J, Breban M, Maksymowych WP (2002) Therapy for 
ankylosing spondylitis: new treatment modalities. Best Pract 
Res Clin Rheumatol 16:631–651. http://dx.doi.org/10.1053/b
erh.2002.0245
 12. Old LJ (1985) Tumor necrosis factor (TNF). Science 
230:630–632
 13. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of 
rheumatoid arthritis: what have we learned? Annu Rev Immu-
nol 19:163–196. doi:10.1146/annurev.immunol.19.1.163
 14. Williams RO, Feldmann M, Maini RN (1992) Anti-TNF 
ameliorates joint disease in murine collagen-induced arthri-
tis. Proc Natl Acad Sci USA 89:9784–9788. doi:10.1073/p
nas.89.20.9784
 15. Piguet PF, Grau GE, Vesin C et al (1992) Evolution of colla-
gen arthritis in mice is arrested by treatment with anti-tumour 
necrosis factor (TNF) antibody or a recombinant soluble TNF 
receptor. J Immunol 77:510–514
 16. Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice 
expressing human tumour necrosis factor: a predictive genetic 
model of arthritis. EMBO J 10:4025–4031
 17. Wyeth-ayerst (2001) ENBREL®
 (etanercept)
 18. European Medicines Agency (EMA) (2013) Guideline on simi-
lar biological medicinal products. http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/2013/05/W
C500142978.pdf. Accessed 26 December 2013
 19. Moreland LW, Schiff MH, Baumgartner SW et al (1999) 
Etanercept therapy in rheumatoid arthritis. A randomized, con-
trolled trial. Ann Intern Med 130:478–486
 20. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge 
DJ (2000) Etanercept in the treatment of psoriatic arthritis and 
psoriasis: a randomised trial. Lancet 356:385–390. doi:10.1016/
S0140-6736(00)02530-7
 21. Sterry W, Ortonne J-P, Kirkham B et al (2010) Comparison of 
two etanercept regimens for treatment of psoriasis and psoriatic 
arthritis: PRESTA randomised double blind multicentre trial. 
BMJ 340:c147. doi:10.1136/bmj.c147
 22. Spadaro A, Lubrano E, Ferrara N, Scarpa R (2012) Etanercept 
in psoriatic arthritis. J Rheumatol Suppl 89:74–76. doi:10.3899/
jrheum.120250
 23. Weger W (2010) Current status and new develop-
ments in the treatment of psoriasis and psoriatic arthri-
tis with biological agents. Br J Pharmacol 160:810–820. 
doi:10.1111/j.1476-5381.2010.00702.x
 24. Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylos-
ing spondylitis by inhibition of tumor necrosis factor alpha. N 
Engl J Med 346:1349–1356. doi:10.1056/NEJMoa012664
207Rheumatol Int (2015) 35:197–209 
1 3
 25. Davis JC, Van Der Heijde D, Braun J et al (2003) Recombinant 
human tumor necrosis factor receptor (etanercept) for treating 
ankylosing spondylitis: a randomized, controlled trial. Arthritis 
Rheum 48:3230–3236. doi:10.1002/art.11325
 26. Andreu JL, Otón T, Sanz J (2011) Anti-TNF a therapy in anky-
losing spondylitis: symptom control and structural damage mod-
ification. Reum Clin 7:51–55. doi:10.1016/j.reuma.2009.03.007
 27. Oen KG, Cheang M (1996) Epidemiology of chronic arthritis 
in childhood. Semin Arthritis Rheum 26:575–591. http://dx.
doi.org/10.1016/S0049-0172(96)80009-6
 28. Russo RA, Katsicas MM, Zelazko M (2002) Etanercept in 
systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 
20:723–726
 29. Sacks JJ, Helmick CG, Luo YH et al (2007) Prevalence of and 
annual ambulatory health care visits for pediatric arthritis and 
other rheumatologic conditions in the United States in 2001–
2004. Arthritis Rheum 57:1439–1445. doi:10.1002/art.23087
 30. Gartlehner G, Hansen RA, Jonas BL et al (2008) Biologics 
for the treatment of juvenile idiopathic arthritis: a systematic 
review and critical analysis of the evidence. Clin Rheumatol 
27:67–76. doi:10.1007/s10067-007-0654-6
 31. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in 
children with polyarticular juvenile rheumatoid arthritis. Pedi-
atric Rheumatology Collaborative Study Group. N Engl J Med 
342:763–769. doi:10.1056/NEJM200003163421103
 32. Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use 
of etanercept in polyarticular course juvenile idiopathic arthritis 
over a two year period. Ann Rheum Dis 61:171–173. doi:10.11
36/ard.61.2.171
 33. Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of 
etanercept for the treatment of juvenile idiopathic arthritis 
according to the onset type. Arthritis Rheum 48:1093–1101. 
doi:10.1002/art.10885
 34. Lahdenne P, Vahasalo PH (2003) Infliximab or etanercept in the 
treatment of children with refractory juvenile idiopathic arthri-
tis: an open label study. Ann Rheum Dis 62:245–247. doi:10.11
36/ard.62.3.245
 35. Henrickson M, Reiff A (2004) Prolonged efficacy of etaner-
cept in refractory enthesitis-related arthritis. J Rheumatol 
31:2055–2061
 36. Horneff G, Schmeling H, Biedermann T et al (2004) The 
German etanercept registry for treatment of juvenile idi-
opathic arthritis. Ann Rheum Dis 63:1638–1644. doi:10.1136/
ard.2003.014886
 37. Tse SM, Burgos-Vargas R, Laxer RM (2005) Anti-tumor necro-
sis factor alpha blockade in the treatment of juvenile spondy-
larthropathy. Arthritis Rheum 52:2103–2108. doi:10.1002/
art.21121
 38. Sulpice M, Deslandre CJ, Quartier P (2009) Efficacy 
and safety of TNFalpha antagonist therapy in patients 
with juvenile spondyloarthropathies. Joint Bone Spine 
76:24–27. doi:10.1016/j.jbspin.2008.03.008
 39. Donnithorne KJ, Cron RQ, Beukelman T (2011) Attainment 
of inactive disease status following initiation of TNF-alpha 
inhibitor therapy for juvenile idiopathic arthritis: enthesitis-
related arthritis predicts persistent active disease. J Rheumatol 
38:2675–2681. doi:10.3899/jrheum.110427
 40. Horneff G, Burgos-Vargas R, Constantin T et al (2013) Efficacy 
and safety of open-label etanercept on extended oligoarticular 
juvenile idiopathic arthritis, enthesitis-related arthritis and pso-
riatic arthritis: part 1 (week 12) of the CLIPPER study. Ann 
Rheum Dis 1–9. doi:10.1136/annrheumdis-2012-203046
 41. Gudbrandsdottir S, Larsen R, Sørensen LK et al (2004) TNF 
and LT binding capacities in the plasma of arthritis patients: 
effect of etanercept treatment in juvenile idiopathic arthritis. 
Clin Exp Rheumatol 22:118–124
 42. Gudbrandsdottir S, Bliddal H, Petri A et al (2004) Plasma 
TNF binding capacity profiles during treatment with 
etanercept in rheumatoid arthritis. Scand J Rheumatol 
33:385–388. doi:10.1080/03009740410000921
 43. Meusch U, Rossol M, Baerwald C et al (2009) Outside-to-
inside signaling through transmembrane tumor necrosis factor 
reverses pathologic interleukin-1beta production and deficient 
apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 
60:2612–2621. doi:10.1002/art.24778
 44. Kaymakcalan Z, Sakorafas P, Bose S et al (2009) Comparisons 
of affinities, avidities, and complement activation of adali-
mumab, infliximab, and etanercept in binding to soluble and 
membrane tumor necrosis factor. Clin Immunol 131:308–316. 
doi:10.1016/j.clim.2009.01.002
 45. Fries W, Muja C, Crisafulli C et al (2008) Infliximab and 
etanercept are equally effective in reducing enterocyte APOP-
TOSIS in experimental colitis. Int J Med Sci 5:169–180. doi:10.
7150/ijms.5.169
 46. Herman S, Zurgil N, Machlav S et al (2011) Distinct effects of 
anti-tumor necrosis factor combined therapy on TH1/TH2 bal-
ance in rheumatoid arthritis patients. Clin Vaccine Immunol 
18:1077–1082. doi:10.1128/CVI.00061-11
 47. Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that 
anti-tumor necrosis factor therapy with both etanercept and 
infliximab induces apoptosis in macrophages, but not lympho-
cytes, in rheumatoid arthritis joints: extended report. Arthritis 
Rheum 52:61–72. doi:10.1002/art.20764
 48. Makrygiannakis D, Catrina AI (2012) Apoptosis as a mecha-
nism of action of tumor necrosis factor antagonists in rheu-
matoid arthritis. J Rheumatol 39:679–685. doi:10.3899/jrh
eum.110974
 49. Giragossian C, Clark T, Piché-Nicholas N, Bowman C (2013) 
Neonatal Fc receptor and its role in the absorption, distribution, 
metabolism and excretion of immunoglobulin G-based biother-
apeutics. Curr Drug Metab 14:764–790. doi:10.2174/13892002
113149990099
 50. Kaneko E, Niwa R (2011) Optimizing therapeutic antibody 
function: progress with Fc domain engineering. BioDrugs 25:1–
11. doi:10.2165/11537830-000000000-00000
 51. Zhou H (2005) Clinical pharmacokinetics of etanercept: a 
fully humanized soluble recombinant tumor necrosis fac-
tor receptor fusion protein. J Clin Pharmacol 45:490–497. 
doi:10.1177/0091270004273321
 52. Van Schouwenburg PA, Rispens T, Wolbink GJ (2013) Immuno-
genicity of anti-TNF biologic therapies for rheumatoid arthritis. 
Nat Rev Rheumatol 9:164–172. doi:10.1038/nrrheum.2013.4
 53. Mok CC, van der Kleij D, Wolbink GJ (2013) Drug levels, 
anti-drug antibodies, and clinical efficacy of the anti-TNFα 
biologics in rheumatic diseases. Clin Rheumatol. doi:10.1007/
s10067-013-2336-x
 54. Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to 
therapeutic proteins: impact on PK/PD and efficacy. AAPS J 
14:296–302. doi:10.1208/s12248-012-9340-y
 55. Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenic-
ity of monoclonal antibodies against tumor necrosis factor used 
in chronic immune-mediated inflammatory conditions: system-
atic review and meta-analysis. JAMA Intern Med 1–13. doi:10.
1001/jamainternmed.2013.7430
 56. Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The 
immunogenicity of humanized and fully human antibodies: 
residual immunogenicity resides in the CDR regions. MAbs 
2:256–265. doi:10.4161/mabs.2.3.11641
 57. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ (2010) 
Immunogenicity of protein therapeutics: the key causes, conse-
quences and challenges. Self Nonself 1:314–322. doi:10.4161/
self.1.4.13904
208 Rheumatol Int (2015) 35:197–209
1 3
 58. FDA Arthritis Advisory Committee (2001) ENBREL® 
(etanercept). http://www.fda.gov/ohrms/dockets/ac/01/
briefing/3779b2_02_immunex.pdf. Accessed 26 Nov 2013
 59. World Health Organization WHO (2002) The importance of 
pharmacovigilance—safety monitoring of medicinal prod-
ucts, pp 3–44. http://apps.who.int/medicinedocs/en/d/Js4893e/. 
Accessed 26 Nov 2013
 60. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al (2012) 
Risk of malignancies in patients with rheumatoid arthritis 
treated with biologic therapy: a meta-analysis. JAMA 308:898–
908. doi:10.1001/2012.jama.10857
 61. Disayabutr S, Pattanaprichakul P, Ruangchira-Urai R (2013) A case 
series of sarcoidosis with pulmonary involvement: various clinical 
and radiographic manifestations. J Med Assoc Thail 96:888–897
 62. Tatarkova I, Cetkovska P (2013) Deep vein thrombosis and 
lung cancer in a patient with psoriasis under anti-tumor 
necrosis factor treatment: a case study. Dermatol Ther. 
doi:10.1111/dth.12041
 63. Babino G, Esposito M, Mazzotta A et al (2013) Entecavir and 
intermittent etanercept therapy in a patient with concurrent 
hepatitis B virus infection and psoriasis. Acta Derm Venereol 
93:373–374. doi:10.2340/00015555-1477
 64. US Food and Drug Administration (FDA) (2005) Guidance for 
industry—E2E pharmacovigilance planning. http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma
tion/Guidances/ucm073107.pdf. Accessed 26 Dec 2013
 65. Senabre- JM, Santos-ramírez C, Santos-soler G et al (2013) 
Long-term safety and efficacy of etanercept in the treatment of 
ankylosing spondylitis. Patient Prefer Adherence 7:961–972
 66. European Medicines Agency EMA (2014) Annex I—summary 
of product characteristics. http://www.ema.europa.eu/docs/
en_GB/document_library/EPAR_Product_Information/human/
000262/WC500027361.pdf. Accessed 20 Feb 2014
 67. Biophoenix (2007) Biosimilars, biogenerics and follow-on bio-
logics. http://www.biotechduediligence.com/uploads/6/3/6/7/63
67956/biosimilars_biogenerics_fobs.pdf. Accessed 14 Jan 2014
 68. Browne SM, Al-Rubeai M (2007) Selection methods for high-
producing mammalian cell lines. Trends Biotechnol 25:425–
432. doi:10.1016/j.tibtech.2007.07.002
 69. Calo-Fernández B, Martínez-Hurtado JL (2012) Biosimilars: 
company strategies to capture value from the biologics market. 
Pharmaceuticals (Basel) 5:1393–1408. doi:10.3390/ph5121393
 70. Chirino AJ, Mire-Sluis A (2004) Characterizing biological 
products and assessing comparability following manufacturing 
changes. Nat Biotechnol 22:1383–1391. doi:10.1038/nbt1030
 71. Beck A, Diemer H, Ayoub D et al (2013) Analytical characteri-
zation of biosimilar antibodies and Fc-fusion proteins. TrAC, 
Trends Anal Chem 48:81–95. doi:10.1016/j.trac.2013.02.014
 72. Chang BS, Hershenson S (2002) Practical approaches to pro-
tein formulation development. Pharm Biotechnol 13:1–25. 
doi:10.1007/978-1-4615-0557-0_1
 73. Tan Q, Guo Q, Fang C et al (2012) Characterization and com-
parison of commercially available TNF receptor 2-Fc fusion 
protein products. MAbs 4:761–774. doi:10.4161/mabs.22276
 74. Schellekens H (2009) Biosimilar therapeutics-what do we need 
to consider? NDT Plus 2:i27–i36. doi:10.1093/ndtplus/sfn177
 75. European Medicines Agency (EMA) (2013) Guideline on 
similar biological medicinal products containing monoclonal 
antibodies – non-clinical and clinical issues. http://www.ema.
europa.eu/docs/en_GB/document_library/Scientific_guideline/2
013/06/WC500144124.pdf . Accessed 26 December 2013
 76. US Food and Drug Administration (FDA) (2010) Title VII: 
improving access to innovative medical therapies. Subtitle A: 
biologic price competition and innovation (BPCIA) Provisions 
of the Patient Protection and Affordable Care Act (PPACA). 
http://www.fda.gov/downloads/Drugs/. Accessed 26 Dec 2013
 77. Kay J (2011) Biosimilars: a regulatory perspective from Amer-
ica. Arthritis Res Ther 13:112. doi:10.1186/ar3310
 78. US Food and Drug Administration (FDA) (2012) Guidance for 
industry scientific considerations in demonstrating biosimilarity 
to a reference product. http://www.fda.gov/downloads/Drugs/G
uidanceComplianceRegulatoryInformation/Guidances/UCM29
1128.pdf. Accessed 26 Dec 2013
 79. US Food and Drug Administration (FDA) (2012) Guidance for 
industry biosimilars: questions and answers regarding imple-
mentation of the Biologics Price Competition and Innovation 
Act of 2009. http://www.fda.gov/downloads/Drugs/GuidanceC
omplianceRegulatoryInformation/Guidances/UCM273001.pdf. 
Accessed 26 Dec 2013
 80. US Food and Drug Administration (FDA) (2012) Guidance for 
industry quality considerations in demonstrating biosimilarity 
to a reference protein product. http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM291134.pdf. Accessed 26 Dec 2013
 81. Azevedo VF, Sandorff E, Siemak B, Halbert RJ (2012) Potential 
regulatory and commercial environment for biosimilars in Latin 
America. Value Heal Reg Issues 1:228–234
 82. Azevedo VF (2010) Are we prepared to prescribe biosimilars? 
Rev Bras Reumatol 50:221–224. http://dx.doi.org/10.1590/
S0482-50042010000300002
 83. Azevedo VF (2013) Biosimilars require scientifically reli-
able comparative clinical data. Rev Bras Reum 53:127–
131. http://dx.doi.org/10.1590/S0482-50042013000100013
 84. Simoens S, Huys I (2013) Market entry of biosimilar low-
molecular-weight heparins in Europe: opportunities and 
challenges. Semin Thromb Hemost 39:250–257. doi:10.105
5/s-0032-1328970
 85. European Genereric Medicines Association (EGA) (2011) Bio-
similars handbook, 2nd ed. EGA. http://www.egagenerics.com/
index.php?option=com_dtracker&filename=EGA_BIOSIMIL
ARS_handbook_en.pdf&filetitle=EGA_BIOSIMILARS_hand-
book_en.pdf. Accessed 12 December 2013
 86. Hodgson J (2009) WHO guidelines presage US bio-
similars legislation? Nat Biotechnol 27:963–965. 
doi:10.1038/nbt1109-963a
 87. Jelkmann W (2010) Biosimilar epoetins and other “follow-on” 
biologics: update on the European experiences. Am J Hematol 
85:771–780. doi:10.1002/ajh.21805
 88. Mellstedt H (2013) Clinical considerations for bio-
similar antibodies. EJC Suppl 11:1–11. doi:10.1016/
S1359-6349(13)70001-6
 89. Chopra A, Shankar S (2012) Biosimilar DMARD in rheumatol-
ogy: a general perspective with focus on India. Indian J Rheu-
matol 7:89–96. doi:10.1016/j.injr.2012.04.005
 90. Yi S, Kim SE, Park MK et al (2012) Comparative pharmacoki-
netics of HD203, a biosimilar of etanercept, with marketed 
etanercept (Enbrel®): a double-blind, single-dose, crosso-
ver study in healthy volunteers. BioDrugs 26(3):177–184. 
doi:10.2165/11631860-000000000-00000
 91. Gu N, Yi S, Kim T-E et al (2011) Comparative pharmacokinet-
ics and tolerability of branded etanercept (25 mg) and its bio-
similar (25 mg): a randomized, open-label, single-dose, two-
sequence, crossover study in healthy Korean male volunteers. 
Clin Ther 33:2029–2037. doi:10.1016/j.clinthera.2011.10.022
 92. Scaramuzzo M (2013) Projetos de biossimilares começam a sair 
do papel. In: Valor Econômico. http://www.valor.com.br/empre
sas/3227390/projetos-de-biossimilares-comecam-sair-do-papel. 
Accessed 26 Oct 2013
 93. Brazilian Ministry of Health (2013) MS atrai inves-
timentos de R$ 1 bilhão para a produção de 
biofármacos. http://www.blog.saude.gov.br/
index.php/programasecampanhas/33290-ministerio-da-
209Rheumatol Int (2015) 35:197–209 
1 3
saude-atrai-investimentos-para-a-producao-de-biofarmacos 
[Portuguese]. Accessed 10 Dec 2013
 94. Protalix Biotherapeutics (2013) PRX-106. http://www.protalix.
com/development-pipeline/prx-106-autoimmune.asp. Accessed 
10 December 2013
 95. Chemo (2013) Libbs and mAbxience sign agreement for biosimi-
lars in Brazil. http://www.chemogroup.com/2013/04/22/mabxie
nce-libbs-signed-agreement-brasilia-2/. Accessed 16 Nov 2013
 96. Mabxience (2013) Four Biosimilars Compounds Reaching 
Clinical Stage in 2013. http://www.mabxience.com/products/. 
Accessed 14 November 2013
 97. Maity S, Ullanat R, Lahiri S et al (2011) A non-innovator ver-
sion of etanercept for treatment of arthritis. Biologicals 39:384–
395. doi:10.1016/j.biologicals.2011.08.014
 98. Lee J-H, Cho JH, Yeo J et al (2013) The pharmacology study of 
a new recombinant TNF receptor-hyFc fusion protein. Biologi-
cals 41:77–83. doi:10.1016/j.biologicals.2012.09.001
 99. Lee J-H, Yeo J, Park HS et al (2013) Biochemical characteri-
zation of a new recombinant TNF receptor-hyFc fusion pro-
tein expressed in CHO cells. Protein Expr Purif 87:17–26. 
doi:10.1016/j.pep.2012.09.001
 100. Dörner T, Strand V, Castañeda-Hernández G et al (2013) 
The role of biosimilars in the treatment of rheumatic dis-
eases. Ann Rheum Dis 72:322–328. doi:10.1136/annrheum
dis-2012-202715
 101. Schellekens H (2004) How similar do “biosimilars” need to be? 
Nat Biotechnol 22:1357–1359. doi:10.1038/nbt1104-1357
 102. Wu B, Wilson A, Wang F et al (2012) Cost effectiveness of 
different treatment strategies in the treatment of patients with 
moderate to severe rheumatoid arthritis in china. PLoS ONE 
7:e47373. doi:10.1371/journal.pone.0047373
 103. Rondon F, Bautista A, Salazar JC et al (2010) Etanar therapy 
in real-life patients with rheumatoid arthritis. Arthritis Rheum 
62(10):1811. doi:10.1002/art.29576
 104. Biosimilarnews (2013) Cipla launches first biosimilar etaner-
cept in India. http://www.biosimilarnews.com/cipla-launches-
first-biosimilar-etanercept-in-india. Accessed 26 Nov 2013
 105. Moctezuma JF, Martinez A, Enkerlin H et al (2013) Compara-
tive, randomized, simple blind to evaluate efficacy and safety 
of Infinitam® (etanercept), associated with methotrexate com-
pared with Enbrel® (etanercept) associated with methotrex-
ate in patients with moderate and severe rheumatoid arthritis. 
Program and abstracts of the European League Against Rheu-
matism (EULAR) Congress 2013; June 12-15, 2013; Madrid, 
Spain. Abstract THU0208 
 106. Declerck PJ (2007) Biotherapeutics in the era of biosimilars: 
what really matters is patient safety. Drug Saf 30:1087–1092
 107. European Medicines Agency (EMA) (2013) Guideline on similar 
biological medicinal products containing biotechnology-derived 
proteins as active substance: quality issues. http://www.ema.
europa.eu/docs/en_GB/document_library/Scientific_guideline/20
13/06/WC500144124.pdf. Accessed 15 Feb 2014
 108. Lee JF, Litten JB, Grampp G (2012) Comparability and biosim-
ilarity: considerations for the healthcare provider. Curr Med Res 
Opin 28:1053–1058. doi:10.1185/03007995.2012.686902
 109. ICH Harmonised Tripartite Guideline (2004) Comparability of 
biotechnological/biological products subject to changes in their 
manufacturing process Q5E. http://www.ich.org/fileadmin/Pub-
lic_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/
Q5E_Guideline.pdf. Accessed 26 Nov 2013
 110. Hassett B, McMillen S, Fitzpatrick B (2014) Characterization 
and comparison of commercially available TNF receptor 2-Fc 
fusion protein products: letter to the editor. MAbs 5:624–625. 
doi:10.4161/mabs.25817
 111. Schiestl M, Stangler T, Torella C et al (2011) Acceptable 
changes in quality attributes of glycosylated biopharmaceuti-
cals. Nat Biotechnol 29:310–312. doi:10.1038/nbt.1839
 112. European Medicines Agency (EMA) (2006) Refusal assessment 
report for Alpheon. http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_Public_assessment_report/human/000
585/WC500070792.pdf. Accessed 26 Nov 2013
 113. NIH (2013) A study comparing SB4 to Enbrel®
 in subjects with 
moderate to severe rheumatoid arthritis despite methotrexate ther-
apy. http://clinicaltrials.gov/show/NCT01895309. Accessed 26 
Nov 2013
 114. NIH (2013) Pharmacokinetic, Safety, tolerability and 
immunogenicity study of SB4 in healthy male subjects. 
http://clinicaltrials.gov/show/NCT01865552. Accessed 26 
November 2013
 115. NIH (2013) Study to demonstrate equivalent efficacy and to 
compare safety of biosimilar etanercept (GP2015) and Enbrel 
(EGALITY). http://clinicaltrials.gov/show/NCT01891864. 
Accessed 26 Nov 2013
 116. Chen D-Y, Lai N-S, Lu L-Y et al (2011) A multicenter 
open-label phase I/II study to assess the safety, tolerabil-
ity, and efficacy of three dose levels of TuNEX in patients 
with rheumatoid arthritis. J Chin Med Assoc 74:544–551. 
doi:10.1016/j.jcma.2011.10.009
 117. NIH (2013) Study to compare the safery and pharmacokinetic 
characteristics of LBEC0101 25 mg with those of Enbrel®. 
http://clinicaltrials.gov/show/NCT01725620. Accessed 14 Jan 
2014
 118. NIH (2012) Comparison the safety and pharmacokinetic char-
acteristics of DWP422 25 mg with those of ENBREL 25MG 
PFS INJ. After subcutaneous injection in healthy male volun-
teers. http://clinicaltrials.gov/show/NCT01635686. Accessed 26 
Nov 2013
 119. Biosciences C (2013) Coherus announces CHS-0214 (pro-
posed etanercept biosimilar) meets primary endpoint in pivotal 
pharmacokinetic clinical study. http://www.coherus.com/press-
releases/coherus-announces-chs-0214-proposed-etanercept-
biosimilar-meets-primary-endpoint-in-pivotal-pharmacokinetic-
clinical-study/. Accessed 26 Nov 2013
